158 related articles for article (PubMed ID: 26186454)
1. The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3.
Zhang Y; Liu R; Fan D; Shi R; Yang M; Miao Q; Deng ZQ; Qian J; Zhen Y; Xiong D; Wang J
Cancer Biol Ther; 2015; 16(10):1514-25. PubMed ID: 26186454
[TBL] [Abstract][Full Text] [Related]
2. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
[TBL] [Abstract][Full Text] [Related]
3. The Nup98::Nsd1 fusion gene induces CD123 expression in 32D cells.
Okamoto K; Imamura T; Tanaka S; Urata T; Yoshida H; Shiba N; Iehara T
Int J Hematol; 2023 Aug; 118(2):277-287. PubMed ID: 37173550
[TBL] [Abstract][Full Text] [Related]
4. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
[No Abstract] [Full Text] [Related]
5. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.
Wang M; Wu H; Duan M; Yang Y; Wang G; Che F; Liu B; He W; Li Q; Zhang L
Life Sci; 2019 Sep; 232():116663. PubMed ID: 31323275
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.
Aref S; Azmy E; El Ghannam D; Haroun M; Ibrahim L; Sabry M
Cancer Biomark; 2020; 29(1):9-16. PubMed ID: 32417762
[TBL] [Abstract][Full Text] [Related]
7. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
9. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
[TBL] [Abstract][Full Text] [Related]
10. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
11. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34
Mani R; Goswami S; Gopalakrishnan B; Ramaswamy R; Wasmuth R; Tran M; Mo X; Gordon A; Bucci D; Lucas DM; Mims A; Brooks C; Dorrance A; Walker A; Blum W; Byrd JC; Lozanski G; Vasu S; Muthusamy N
Haematologica; 2018 Aug; 103(8):1288-1297. PubMed ID: 29773600
[TBL] [Abstract][Full Text] [Related]
12. Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.
Aldoss I; Clark M; Song JY; Pullarkat V
Hum Vaccin Immunother; 2020 Oct; 16(10):2341-2348. PubMed ID: 32692611
[TBL] [Abstract][Full Text] [Related]
13. CD123 Antagonistic Peptides Assembled with Nanomicelles Act as Monotherapeutics to Combat Refractory Acute Myeloid Leukemia.
Xu S; Zhang M; Fang X; Hu X; Xing H; Yang Y; Meng J; Wen T; Liu J; Wang J; Wang C; Xu H
ACS Appl Mater Interfaces; 2022 Aug; 14(34):38584-38593. PubMed ID: 35977045
[TBL] [Abstract][Full Text] [Related]
14. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
[TBL] [Abstract][Full Text] [Related]
15. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.
Xie LH; Biondo M; Busfield SJ; Arruda A; Yang X; Vairo G; Minden MD
Blood Cancer J; 2017 Jun; 7(6):e567. PubMed ID: 28574487
[TBL] [Abstract][Full Text] [Related]
16. Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarker.
Abdollahpour-Alitappeh M; Razavi-Vakhshourpour S; Abolhassani M
Biotechnol Appl Biochem; 2018 Nov; 65(6):841-847. PubMed ID: 29972607
[TBL] [Abstract][Full Text] [Related]
17. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
18. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
[TBL] [Abstract][Full Text] [Related]
19. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
20. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia.
Xu S; Zhang M; Fang X; Meng J; Xing H; Yan D; Liu J; Yang Y; Wen T; Zhang W; Wang J; Wang C; Xu H
J Hematol Oncol; 2021 Nov; 14(1):193. PubMed ID: 34774070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
